The study's lead author told Newsweek that gene editing could become another tool for addressing health problems in dogs.

Verve-102 uses gene editing to target PCSK9 and lower LDL cholesterol after one infusion, showing promising early results but ...

CRISPR Therapeutics (NASDAQ: CRSP) is up only slightly more than 8% so far this year, well under the 27% return of the Nasdaq ...

Agriculture has always evolved through better tools.

Doctors have long debated how to balance the need for safety in gene therapy trials with the urgency of developing treatments ...

Ethical and regulatory guardrails must protect patients amid desperation and scientific op ...

Wall Street analysts are confident that Scribe Therapeutics can continue surging after going public less than a month ago. Three firms initiated coverage of the the gene-based therapeutics ...

For millions of people living with high cholesterol, the routine is familiar and exhausting: a pill every morning, an ...

Two undisclosed deaths in Chinese gene-editing trials renew concerns about trial oversight, safety reporting, and ...

Human testing could take up to five years to ramp up, but AI approaches will yield results in time, Karoly Nikolich says.

Now, there is renewed hope that allergies won't get in the way of pet ownership.

Zilong Qiu is now being investigated by his university more than a year after his patient likely died from his team's experimental gene-editing therapy.